Albendazole for lymphatic filariasis.
Identifieur interne : 003B88 ( PubMed/Checkpoint ); précédent : 003B87; suivant : 003B89Albendazole for lymphatic filariasis.
Auteurs : David Addiss ; Julia Critchley ; Henry Ejere ; Paul Garner ; Hellen Gelband ; Carrol GambleSource :
- The Cochrane database of systematic reviews [ 1469-493X ] ; 2004.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Albendazole, Diéthylcarbamazine, Filaricides, Ivermectine.
- Essais contrôlés randomisés comme sujet, Humains.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Albendazole, Diethylcarbamazine, Filaricides, Ivermectin.
- drug therapy : Elephantiasis, Filarial.
- Humans, Randomized Controlled Trials as Topic.
Abstract
Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to eliminate lymphatic filariasis.
DOI: 10.1002/14651858.CD003753.pub2
PubMed: 14974034
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:14974034Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Albendazole for lymphatic filariasis.</title><author><name sortKey="Addiss, David" sort="Addiss, David" uniqKey="Addiss D" first="David" last="Addiss">David Addiss</name></author><author><name sortKey="Critchley, Julia" sort="Critchley, Julia" uniqKey="Critchley J" first="Julia" last="Critchley">Julia Critchley</name></author><author><name sortKey="Ejere, Henry" sort="Ejere, Henry" uniqKey="Ejere H" first="Henry" last="Ejere">Henry Ejere</name></author><author><name sortKey="Garner, Paul" sort="Garner, Paul" uniqKey="Garner P" first="Paul" last="Garner">Paul Garner</name></author><author><name sortKey="Gelband, Hellen" sort="Gelband, Hellen" uniqKey="Gelband H" first="Hellen" last="Gelband">Hellen Gelband</name></author><author><name sortKey="Gamble, Carrol" sort="Gamble, Carrol" uniqKey="Gamble C" first="Carrol" last="Gamble">Carrol Gamble</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:14974034</idno><idno type="pmid">14974034</idno><idno type="doi">10.1002/14651858.CD003753.pub2</idno><idno type="wicri:Area/PubMed/Corpus">004070</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004070</idno><idno type="wicri:Area/PubMed/Curation">004070</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004070</idno><idno type="wicri:Area/PubMed/Checkpoint">004070</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004070</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Albendazole for lymphatic filariasis.</title><author><name sortKey="Addiss, David" sort="Addiss, David" uniqKey="Addiss D" first="David" last="Addiss">David Addiss</name></author><author><name sortKey="Critchley, Julia" sort="Critchley, Julia" uniqKey="Critchley J" first="Julia" last="Critchley">Julia Critchley</name></author><author><name sortKey="Ejere, Henry" sort="Ejere, Henry" uniqKey="Ejere H" first="Henry" last="Ejere">Henry Ejere</name></author><author><name sortKey="Garner, Paul" sort="Garner, Paul" uniqKey="Garner P" first="Paul" last="Garner">Paul Garner</name></author><author><name sortKey="Gelband, Hellen" sort="Gelband, Hellen" uniqKey="Gelband H" first="Hellen" last="Gelband">Hellen Gelband</name></author><author><name sortKey="Gamble, Carrol" sort="Gamble, Carrol" uniqKey="Gamble C" first="Carrol" last="Gamble">Carrol Gamble</name></author></analytic><series><title level="j">The Cochrane database of systematic reviews</title><idno type="eISSN">1469-493X</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Albendazole (therapeutic use)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Ivermectin (therapeutic use)</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Albendazole (usage thérapeutique)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Essais contrôlés randomisés comme sujet</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Humains</term><term>Ivermectine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Albendazole</term><term>Diethylcarbamazine</term><term>Filaricides</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Albendazole</term><term>Diéthylcarbamazine</term><term>Filaricides</term><term>Ivermectine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to eliminate lymphatic filariasis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14974034</PMID><DateCreated><Year>2004</Year><Month>02</Month><Day>19</Day></DateCreated><DateCompleted><Year>2004</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1469-493X</ISSN><JournalIssue CitedMedium="Internet"><Issue>1</Issue><PubDate><Year>2004</Year></PubDate></JournalIssue><Title>The Cochrane database of systematic reviews</Title><ISOAbbreviation>Cochrane Database Syst Rev</ISOAbbreviation></Journal><ArticleTitle>Albendazole for lymphatic filariasis.</ArticleTitle><Pagination><MedlinePgn>CD003753</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mass treatment with albendazole, co-administered with another antifilarial drug, is being promoted as part of a global programme to eliminate lymphatic filariasis.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To assess the effects of albendazole on patients or populations with filarial infection, and on morbidity in patients with filarial infection; and to assess the frequency of adverse events for albendazole both given singly or in combination with another antifilarial drug (diethylcarbamazine or ivermectin).</AbstractText><AbstractText Label="SEARCH STRATEGY" NlmCategory="METHODS">We searched the Cochrane Infectious Disease Group's trial register (September 2003), the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 3, 2003), MEDLINE (September 2003), EMBASE (September 2003), LILACS (September 2003); and checked the reference lists and contacted experts, international organizations, and a pharmaceutical company.</AbstractText><AbstractText Label="SELECTION CRITERIA" NlmCategory="METHODS">Randomized and quasi-randomized controlled trials of albendazole singly or in combination with anti-filarial drugs in people or populations with lymphatic filariasis.</AbstractText><AbstractText Label="DATA COLLECTION AND ANALYSIS" NlmCategory="METHODS">Two reviewers assessed eligibility and trial methodological quality. We calculated relative risks (RR) with 95% confidence intervals (CI) for binary outcomes, and where appropriate, combined them in a meta-analysis using the fixed effect model or random effects model.</AbstractText><AbstractText Label="MAIN RESULTS" NlmCategory="RESULTS">Four small studies met the inclusion criteria (a total of 2473 children and adults, of whom 536 had detectable microfilariae). No effect of albendazole on microfilaraemia was demonstrated in two studies (placebo controlled, RR 0.97, 95%CI 0.87 to 1.09, n = 195). When compared to ivermectin, albendazole performed worse (RR 0.84, 95% CI 0.72 to 0.98, 2 studies of patients initially microfilariae positive, n = 198). When compared to diethylcarbamazine, no statistically significant difference was detected, but numbers were small (n = 56). Two studies compared albendazole plus ivermectin to ivermectin alone on the presence of microfilaraemia. Results were mixed: one study showed the combination to be more effective (RR 0.27, 95% CI 0.11 to 0.70, n = 52), but the other did not demonstrate a statistically significant difference (RR 1.04, 95% CI 0.87 to 1.25, n = 145). A further study compared albendazole plus diethylcarbamazine to diethylcarbamazine alone and did not demonstrate a difference on microfilaraemia prevalence (RR 1.57, 95% CI 0.44 to 5.60, n=35). No study examined the effects of the drugs on adult worms.</AbstractText><AbstractText Label="REVIEWER'S CONCLUSIONS" NlmCategory="CONCLUSIONS">There is insufficient reliable research to confirm or refute whether albendazole alone, or co-administered with diethylcarbamazine or ivermectin, has an effect on lymphatic filariasis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Addiss</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Critchley</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ejere</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Garner</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gelband</LastName><ForeName>Hellen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Gamble</LastName><ForeName>Carrol</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><CollectiveName>International Filariasis Review Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cochrane Database Syst Rev</MedlineTA><NlmUniqueID>100909747</NlmUniqueID><ISSNLinking>1361-6137</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005369">Filaricides</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>F4216019LN</RegistryNumber><NameOfSubstance UI="D015766">Albendazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber><NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Cochrane Database Syst Rev. 2005;(4):CD003753</RefSource><PMID Version="1">16235339</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D015766" MajorTopicYN="N">Albendazole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>55</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14974034</ArticleId><ArticleId IdType="doi">10.1002/14651858.CD003753.pub2</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Addiss, David" sort="Addiss, David" uniqKey="Addiss D" first="David" last="Addiss">David Addiss</name><name sortKey="Critchley, Julia" sort="Critchley, Julia" uniqKey="Critchley J" first="Julia" last="Critchley">Julia Critchley</name><name sortKey="Ejere, Henry" sort="Ejere, Henry" uniqKey="Ejere H" first="Henry" last="Ejere">Henry Ejere</name><name sortKey="Gamble, Carrol" sort="Gamble, Carrol" uniqKey="Gamble C" first="Carrol" last="Gamble">Carrol Gamble</name><name sortKey="Garner, Paul" sort="Garner, Paul" uniqKey="Garner P" first="Paul" last="Garner">Paul Garner</name><name sortKey="Gelband, Hellen" sort="Gelband, Hellen" uniqKey="Gelband H" first="Hellen" last="Gelband">Hellen Gelband</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B88 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003B88 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:14974034
|texte= Albendazole for lymphatic filariasis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:14974034" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |